Dementia With Lewy Bodies


Quick Start: Dementia With Lewy Bodies

Definition
  • Dementia with Lewy bodies (DLB) is a neurodegenerative disease of the brain characterized:

    • clinically by dementia, fluctuating attention and alertness, visual hallucinations, rapid-eye movement (REM) sleep behavior disorder, and parkinsonism, and

    • pathologically by Lewy body formation and abnormal alpha-synuclein metabolism.

  • Mild cognitive impairment with Lewy bodies is similar to DLB but with preserved or minimally affected function.

Prevalence
  • DLB is one of the most common neurodegenerative diseases of the brain, accounting for approximately 7.5% of all dementias in secondary care. It frequently co-occurs with Alzheimer’s and/or vascular pathology.

Genetic risk
  • There are familial cases of DLB related to mutations or repeats of the alpha-synuclein gene located on chromosome 4. Most patients, however, do not show abnormalities of this gene.

Cognitive and other symptoms
  • Impairment in attention, executive function, and visuospatial ability are often prominent. Memory impairment may or may not be prominent initially.

  • Sleep disturbances are common in DLB, and often leads to disrupted circadian rhythm, fluctuating levels of attention and alertness, and REM sleep behavior disorder.

Summary of diagnostic criteria Essential for a diagnosis:

  • Dementia.

Core clinical features:

  • Fluctuating cognition with pronounced variations in attention and alertness.

  • Recurrent visual hallucinations, typically well-formed and detailed.

  • REM sleep behavior disorder, which may precede cognitive decline.

  • One or more spontaneous features of parkinsonism: bradykinesia, rest tremor, or rigidity.

Indicative biomarkers:

  • Reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET imaging.

  • Abnormal (low uptake) 123 iodine-MIBG myocardial scintigraphy.

  • Polysomnographic confirmation of REM sleep without atonia.

Probable DLB can be diagnosed if:

  • a.

    Two or more core clinical features of DLB are present, with or without the presence of indicative biomarkers, or

  • b.

    Only one core clinical feature is present, but with one or more indicative biomarkers.

Possible DLB can be diagnosed if:

  • a.

    Only one core clinical feature of DLB is present, with no indicative biomarker evidence, or

  • b.

    One or more indicative biomarkers is present but there are no core clinical features.

Treatment
  • Cholinesterase inhibitors are beneficial; rivastigmine (Exelon) has been approved by the U.S. Food and Drug Administration (FDA).

  • Other medications, including levodopa/carbidopa (Sinemet), memantine, selective serotonin reuptake inhibitors, pimavanserin, and atypical antipsychotics, may be used with caution.

Top differential diagnoses
  • Alzheimer’s disease, mixed dementia (DLB plus Alzheimer’s disease), vascular dementia, progressive supranuclear palsy, corticobasal degeneration, and chronic traumatic encephalopathy.

A 65-year-old man came to the clinic complaining of cognitive difficulties. He had been forgetful for about a year, often confused, and was unable to use the television remote. Although he was generally oriented to the day, date, month, and year, he would get lost—even on familiar routes. He could no longer balance his checkbook or learn a new computer program. He had less volume in his voice, less expression in his face, and his walking had slowed down. On review of systems he admitted to having visual hallucinations of people and animals—which he did not mention for fear of being considered crazy. When asked about sleep, his wife noted that for more than five years he had been kicking and sometimes punching or wrestling her while asleep, such that she often ended up sleeping in a different bed. On examination he had masked facies, increased tone, cogwheeling, and a shuffling gait.

Prevalence, Prognosis, and Definition

Dementia with Lewy bodies (DLB) is a neurodegenerative disease of the brain characterized clinically by dementia, fluctuating attention and alertness, visual hallucinations, rapid-eye movement (REM) sleep behavior disorder, and/or parkinsonism, and pathologically by Lewy body formation and abnormal alpha-synuclein metabolism. Parkinson’s disease dementia (PDD) is a clinical diagnosis of dementia occurring in someone who already has Parkinson’s disease diagnosed at least one year before the onset of dementia. Pathologically, the cognitive deficits in Parkinson’s disease dementia are usually due to Lewy bodies, although they may be due to other pathologies, such as Alzheimer’s disease. Lewy body dementia is the “umbrella” term for a clinical diagnosis of either DLB or PDD. Mild cognitive impairment with Lewy bodies is prodromal dementia with Lewy bodies, that is, similar to dementia with Lewy bodies but with preserved or minimally affected function. Parkinson’s disease mild cognitive impairment (PD-MCI) is a clinical diagnosis of mild cognitive impairment in someone who already has Parkinson’s disease. It may be a prodromal stage of either dementia with Lewy bodies or Parkinson’s disease dementia, depending upon how quickly the cognitive symptoms start after the diagnosis of Parkinson’s disease. Lastly, Lewy body disease refers to the pathologic state of Lewy bodies in the brain seen in both Lewy body dementia and Parkinson’s disease ( ). (See Table 8.1 .)

Table 8.1
Comparison Between Alzheimer’s and Lewy Body Diseases
Lewy Body Diseases Alzheimer’s Diseases
Parkinson’s Disease Parkinson’s Disease Mild Cognitive Impairment Mild Cognitive Impairment With Lewy Bodies Lewy Body Dementia Mild Cognitive Impairment Due to Alzheimer’s Disease Alzheimer’s Disease Dementia
Parkinson’s Disease Dementia Dementia With Lewy Bodies
Motor symptoms Parkinsonism present Parkinsonism present Parkinsonism may or may not be present. Tremor less likely Parkinsonism present Parkinsonism may or may not be present. Tremor less likely None None (until the late stages)
Cognitive deficits Essentially none Mild visuospatial, attentional, and executive function deficits Mild visuospatial, attentional, and executive function deficits Visuospatial, attentional, and executive function prominent Visuospatial, attentional, and executive function prominent Mild memory, word finding, visuospatial, and executive function Memory, word finding, visuospatial, and executive function prominent
Behavioral and psycho-logical symptoms Anxiety, depression, and apathy common. Rapid-eye movement (REM) sleep behavior disorder may be present. Anxiety, depression, and apathy common. Hallucinations and REM sleep behavior disorder may be present. Anxiety, depression, and apathy common. Hallucinations and REM sleep behavior disorder may be present. Anxiety, depression, apathy common, plus others as disease progresses. Hallucinations and REM sleep behavior disorder may be present. Anxiety, depression, apathy common, plus others as disease progresses. Hallucinations and REM sleep behavior disorder often present. Anxiety and depression common Anxiety, depression, apathy common, plus others as disease progresses
Bodily function Anosmia and constipation common Anosmia and constipation common Anosmia and constipation common Anosmia and constipation common Anosmia and constipation common Anosmia common Anosmia common
Activities of daily living No impairment from cognition No impairment from cognition No impairment from cognition Impaired from cognition Impaired from cognition No impairment from cognition Impaired from cognition
Underlying pathology Lewy bodies in brainstem Lewy bodies in brainstem plus Lewy bodies in cortex and/or Alzheimer’s pathology Lewy bodies in cortex±brainstem. May also have Alzheimer’s pathology Lewy bodies in brainstem plus Lewy bodies in cortex (high likelihood) and/or Alzheimer’s pathology (low likelihood) Lewy bodies in cortex±brainstem. High likelihood of concomitant Alzheimer’s pathology Alzheimer’s pathology Alzheimer’s pathology

Does all this terminology seem a bit confusing? In practice, Parkinson’s disease mild cognitive impairment and Parkinson’s disease dementia are not difficult to diagnose because they are essentially the development of mild cognitive impairment and dementia, respectively, in a patient with established Parkinson’s disease. In this chapter, we will focus on understanding dementia with Lewy bodies and its prodromal state, mild cognitive impairment with Lewy bodies, so that these disorders can be distinguished from others that they are commonly confused with, including Alzheimer’s disease (see Chapter 4 ), progressive supranuclear palsy (see Chapter 12 ), corticobasal degeneration (see Chapter 13 ), and chronic traumatic encephalopathy (see Chapter 15 ).

Dementia with Lewy bodies is either the second or third most common neurodegenerative cause of dementia in the older adult after Alzheimer’s disease (see Chapter 4 ) or Alzheimer’s and limbic-predominant age-related TDP-43 encephalopathy (LATE) (see Chapter 6 ), depending upon the age range of those studied ( ). One meta-analysis found the incidence of new cases of dementia with Lewy bodies to be 3.8%, with a prevalence of about 4.2% in the community and 7.5% of all dementias in secondary care ( ). Another study found the incidence in a county in Minnesota was estimated at 5.9 per 100,000 ( ).

Although some studies have suggested that the prognosis of patients with dementia with Lewy bodies is similar to those with Alzheimer’s disease, other studies suggest that patients with dementia with Lewy bodies show a more rapid decline in function, leading to earlier nursing home placement and death. Our clinical experience is that most patients with dementia with Lewy bodies do progress more rapidly than those with Alzheimer’s disease. The combination of parkinsonism, dementia, and visual hallucinations typically leads to nursing home placement in 2 to 6 years, and death in 3 to 8 years. One study found median survival of patients with dementia with Lewy bodies to be 3.7 years ( ), and another found survival of patients with Parkinson’s disease dementia to be 4.5 years ( ). There are, however, exceptions of patients who show a much slower disease progression.

Note that many patients with dementia with Lewy bodies also meet clinical and pathological criteria for Alzheimer’s disease, with some studies suggesting an overlap of greater than 90% ( ). Thus many patients have a mixed dementia of Alzheimer’s disease and dementia with Lewy bodies.

Criteria and Diagnosis

The most important features of dementia with Lewy bodies are dementia (which must of course always be present), rapid-eye movement (REM) sleep behavior disorder, fluctuating cognition, visual hallucinations, and parkinsonism ( Fig. 8.1 ). Criteria for mild cognitive impairment with Lewy bodies have been published ( ). Although technically for research, they are immediately useful, as patients with mild cognitive impairment, preserved independent function, and features of dementia with Lewy bodies commonly present to the clinic. See Boxes 8.1–8.3 for a summary of the current clinical diagnostic criteria (see Chapter 3 for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition general criteria for major and mild neurocognitive disorder). Regarding the parkinsonism, note that up to 25% of patients with autopsy-proven dementia with Lewy bodies showed no signs of parkinsonism during life, perhaps due to having mainly cortical and little brainstem pathology. Note that biomarkers can now be used in support of a probable dementia with Lewy bodies diagnosis, namely reduced dopamine transporter uptake in basal ganglia demonstrated by single photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging, abnormal (low uptake) 123 iodine–meta-iodobenzylguanidine (MIBG) myocardial scintigraphy, and polysomnographic confirmation of REM sleep without atonia.

Fig. 8.1, Major clinical and pathological abnormalities in dementia with Lewy bodies.

Box 8.1
Revised Criteria for the Clinical Diagnosis of Probable and Possible Dementia With Lewy Bodies
Modified from McKeith, I. G., Boeve, B. F., Dickson, D. W., et al. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 89 (1), 88–100.

Essential for a diagnosis:

  • Dementia defined as progressive cognitive decline sufficient to interfere with normal social or occupational function, or with usual daily activities. Deficits on tests of attention, executive function, and visuospatial ability may be prominent and occur early. Memory impairment is usually evident with progression.

Core clinical features (the first three typically occur early and may persist):

  • Fluctuating cognition with pronounced variations in attention and alertness.

  • Recurrent visual hallucinations that are typically well formed and detailed.

  • Rapid-eye movement (REM) sleep behavior disorder, which may precede cognitive decline.

  • One or more spontaneous features of parkinsonism: bradykinesia, rest tremor, or rigidity.

Supportive clinical features:

  • Severe sensitivity to antipsychotic agents.

  • Postural instability.

  • Repeated falls.

  • Syncope or other transient episodes of unresponsiveness.

  • Severe autonomic dysfunction (e.g., constipation, orthostatic hypotension, urinary incontinence).

  • Hypersomnia.

  • Hyposmia.

  • Hallucinations in other modalities.

  • Systematized delusions.

  • Apathy, anxiety, and depression.

Indicative biomarkers:

  • Reduced dopamine transporter uptake in basal ganglia demonstrated by single photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging.

  • Abnormal (low uptake) 123 iodine-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy.

  • Polysomnographic confirmation of rapid-eye movement sleep without atonia.

Supportive biomarkers:

  • Relative preservation of medial temporal lobe structures on computed tomography/magnetic resonance imaging scan.

  • Generalized low uptake on SPECT/PET perfusion/metabolism scan with reduced occipital activity ± the cingulate island sign on fluorodeoxyglucose-PET imaging.

  • Prominent posterior slow-wave activity on electroencephalogram with periodic fluctuations in the pre-alpha/theta range.

Probable dementia with Lewy bodies (DLB) can be diagnosed if:

  • a.

    Two or more core clinical features of DLB are present, with or without the presence of indicative biomarkers, or

  • b.

    Only one core clinical feature is present, but with one or more indicative biomarkers.

Probable DLB should not be diagnosed on the basis of biomarkers alone.

Possible DLB can be diagnosed if:

  • a.

    Only one core clinical feature of DLB is present, with no indicative biomarker evidence, or

  • b.

    One or more indicative biomarkers is present but there are no core clinical features.

DLB is less likely:

  • a.

    In the presence of any other physical illness or brain disorder, including cerebrovascular disease, sufficient to account in part or in total for the clinical picture, although these do not exclude a DLB diagnosis and may serve to indicate mixed or multiple pathologies contributing to the clinical presentation, or

  • b.

    If parkinsonian features are the only core clinical feature and appear for the first time at a stage of severe dementia.

Box 8.2
Research Criteria for the Clinical Diagnosis of Probable and Possible Mild Cognitive Impairment With Lewy Bodies
Modified from McKeith, I. G., Ferman, T. J., Thomas, A. J., et al. (2020). Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 94 , 743–755.

Essential for a diagnosis is mild cognitive impairment defined by:

  • Concern by the patient, informant, or clinician regarding cognitive decline.

  • Objective evidence of impairment in one or more cognitive domains, more likely to be attention-executive and/or visual processing deficits.

  • Preserved or minimally affected performance of previously attained independence in functional abilities, which do not meet the criteria for dementia.

Core clinical features:

  • Fluctuating cognition with variations in attention and alertness.

  • Recurrent visual hallucinations.

  • Rapid-eye movement (REM) sleep behavior disorder.

  • One or more spontaneous cardinal features of parkinsonism: bradykinesia, rest tremor, or rigidity.

Proposed biomarkers:

  • Reduced dopamine transporter uptake in basal ganglia demonstrated by single photon emission computed tomography or positron emission tomography.

  • Polysomnographic confirmation of rapid-eye movement sleep without atonia.

  • Reduced meta-iodobenzylguanidine (MIBG) uptake on myocardial scintigraphy.

Probable mild cognitive impairment with Lewy bodies can be diagnosed if:

  • Two or more core clinical features are present, with or without the presence of a proposed biomarker, or

  • Only one core clinical feature is present, but with one or more proposed biomarkers.

Probable mild cognitive impairment with Lewy bodies should not be diagnosed based on biomarkers alone .

Possible mild cognitive impairment with Lewy bodies can be diagnosed if:

  • Only one core clinical feature is present, with no proposed biomarkers, or

  • One or more of the proposed biomarkers is present, but there are no core clinical features.

Supportive clinical features:

  • Severe sensitivity to antipsychotic agents.

  • Postural instability.

  • Repeated falls.

  • Syncope or other transient episodes of unresponsiveness.

  • Prolonged or recurrent delirium.

  • Autonomic dysfunction (e.g., constipation, orthostatic hypotension, urinary incontinence).

  • Hypersomnia.

  • Hyposmia.

  • Hallucinations in other modalities including passage and sense of presence phenomena.

  • Systematized delusions.

  • Apathy, anxiety, and depression.

Potential biomarkers of mild cognitive impairment with Lewy bodies:

  • Quantitative electroencephalogram showing slowing and dominant frequency variability.

  • Relative preservation of medial temporal lobe structures on structural imaging (computed tomography/magnetic resonance imaging [CT/MRI]).

  • Insular thinning and gray matter volume loss on MRI.

  • Low occipital uptake on perfusion/metabolism scan.

Mild cognitive impairment plus supportive clinical features or potential biomarkers are insufficient to diagnose mild cognitive impairment with Lewy bodies but may raise suspicion of it and prompt biomarker investigation .

Supportive clinical features or potential biomarkers may add weight to an existing mild cognitive impairment with Lewy bodies diagnosis .

Mild cognitive impairment with Lewy bodies is less likely in the presence of any other physical illness or brain disease, including cerebrovascular disease, sufficient to account in part or in total for the clinical picture, although these do not exclude a mild cognitive impairment with Lewy bodies diagnosis and may serve to indicate mixed or multiple pathologies contributing to the clinical presentation .

Box 8.3
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Criteria for Major or Mild Neurocognitive Disorder With Lewy Bodies
From American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (DSM-5) (5th ed.). Arlington, VA: American Psychiatric Publishing, Inc.

  • A.

    The criteria are met for major or mild neurocognitive disorder.

  • B.

    The disturbance has insidious onset and gradual progression.

  • C.

    The disorder meets a combination of core diagnostic features and suggestive diagnostic features for either probable or possible neurocognitive disorder with Lewy bodies.

    For probable major or mild neurocognitive disorder with Lewy bodies, the individual has two core features, or one suggestive feature with one or more core features. For possible major or mild neurocognitive disorder with Lewy bodies, the individual has only one core feature, or one or more suggestive features.

    • 1.

      Core diagnostic features:

      • a.

        Fluctuating cognition with pronounced variations in attention and alertness.

      • b.

        Recurrent visual hallucinations that are well formed and detailed.

      • c.

        Spontaneous features of parkinsonism, with onset subsequent to the development of cognitive decline.

    • 2.

      Suggestive diagnostic features:

      • a.

        Meets criteria for rapid-eye movement sleep behavior disorder.

      • b.

        Severe neuroleptic sensitivity.

  • D.

    The disturbance is not better explained by cerebrovascular disease, another neurodegenerative disease, the effects of a substance, or another mental, neurological, or systemic disorder.

Regarding the characteristics of the dementia, it may appear identical to Alzheimer’s disease, with memory problems being prominent, or memory may be relatively normal with major difficulties present in attention, executive function, and visuospatial ability. If the dementia appears quite similar to that of Alzheimer’s disease, it is reasonable to presume that (as is common in patients with dementia with Lewy bodies) Alzheimer’s pathology of senile plaques and neurofibrillary tangles is likely present along with Lewy bodies and abnormal alpha-synuclein metabolism. Patients with dementia with Lewy bodies can, however, have prominent memory problems without Alzheimer’s pathology ( ).

Determining whether “fluctuating cognition” is present is quite difficult for most clinicians, for the simple reason that all dementing illnesses produce waxing and waning, with some days and times of day better than others. In our experience, the key aspect of fluctuating cognition to look for is relative dramatic fluctuations of alertness and/or attention that impact functional abilities ( ). In one patient we cared for, this manifested rather dramatically: the patient literally fell asleep during dinner and could not be awakened. Quite reasonably, the family was concerned that he had suffered a stroke or other catastrophic medical illness, and he was taken by ambulance to the hospital. By the time he reached the hospital he had awakened, and was back to baseline (the work-up, including magnetic resonance imaging [MRI], electroencephalogram [EEG], and laboratory studies, was unrevealing). Other patients who we have cared for have had similar, although less dramatic, alterations in alertness.

Visual hallucinations are perhaps the most definitive criteria for dementia with Lewy bodies, and are related to the degree of pathology ( ). In our experience actual well-formed hallucinations of people or animals are simply not present in other disorders (see below for discussion). The hallucinations are usually visual, and are almost always of people or animals, although they are sometimes described as large “bugs.” These hallucinations are remarkable in several ways. First, patients with mild dementia may be fully or partially aware that they are having hallucinations. We have had many patients who can both describe in detail their hallucinations and also know, at least some of the time, that they are not real (i.e. they do not always have a delusional component). During a consultation, one patient said that he could see a man curled up under the desk, but knew that this could not be real. In other cases, the hallucinations can be incredibly realistic, and typically as the dementia progresses there is usually no ability of the patient to separate them from reality. One patient asked his wife why she was not serving dinner to the other people sitting at the table. Another patient thought she was petting an imaginary dog in the waiting room. And another patient used to see little children playing in the corner of the room. This last patient was thought initially to be suffering from a psychotic depression (she had lost a child) until the correct diagnosis was made. Unfortunately, she had already received several courses of electroconvulsive therapy that may have exacerbated her hallucinations and dementia. The cause of visual hallucinations in Lewy body dementia is unknown. One study found an association between the concentration of Lewy bodies in the temporal lobe and well-formed visual hallucinations ( ). However, the hallucinations may also relate to sleep disturbances, as discussed below. Although less common, hallucinations may be in other sensory modalities, including auditory, olfactory, and tactile. Visual hallucinations may also be preceded by prodromal symptoms of seeing things fleetingly “out of the corner of one’s eye” and/or a feeling of a presence (without an abnormal visual perception).

True Hallucinations?

Many families of patients who are suffering from dementias other than dementia with Lewy bodies inform us that the patient is having hallucinations. A common example is the patient with Alzheimer’s disease who reports that she was talking with her mother last night, even though her mother died many years ago. Another example is the patient who reports that people were up having a party in her house all night long. Typically these symptoms are not true hallucinations but are instead memory distortions (thinking that a real memory from long ago happened recently), confabulations, or delusions. Memory distortions and delusions can usually be easily distinguished from true hallucinations because in the former case the patient is never observed to be actively hallucinating. Interestingly, all of these symptoms—true hallucinations, memory distortions, confabulations, and delusions—will often improve, at least partly, with cholinesterase inhibitors. Thus cholinesterase inhibitors should always be used before atypical antipsychotics to treat these symptoms.

Sleep Disturbances

Although we are all normally paralyzed during REM sleep, those with REM sleep behavior disorder are not, and these individuals act out their dreams while sleeping. These actions can be disturbing and even frightening or life threatening to their sleeping partners. It has been noted for a number of years that REM sleep behavior disorder can be one of the earliest signs of dementia with Lewy bodies ( ). One clue as to the reason for this association comes from a patient with dementia with Lewy bodies whose brain at autopsy showed a marked loss of brainstem monoaminergic nuclei (including locus caeruleus and substantia nigra) that inhibit cholinergic neurons in the pedunculopontine nucleus, which usually cause paralysis during REM sleep ( ). When suspecting that a patient may have dementia with Lewy bodies, it is therefore important to ask whether the patient ever acts out his or her dreams while sleeping, or simply moves around a lot in their sleep. Probably the most common sign of this disorder is that the sleeping partner complains that the patient has begun kicking them at night, and frequently by the time the history is taken the spouse has sought refuge by sleeping in another bed! For patients who sleep alone, a telltale sign is that all the covers and pillows are kicked out and strewn about or the patient may actually fall out of bed.

The association of dementia with Lewy bodies and disturbances in alertness, visual hallucinations, and REM sleep behavior disorder has led researchers to investigate whether many of the symptoms of dementia with Lewy bodies are related to a sleep disorder. have found that, although both patients with Alzheimer’s disease and those with dementia with Lewy bodies have disrupted circadian rhythms, the disruption was greatest in those with dementia with Lewy bodies ( ). It may be that in dementia with Lewy bodies disruption of circadian rhythm causes loss of alertness owing to drowsiness or actual sleep, and REM phenomena breaking into wakeful consciousness cause the well-formed visual hallucinations.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here